重组人血管内皮抑素联合5-Fu/DDP序贯腹腔注药治疗胃癌恶性腹水的临床观察

Clinical observation of recombinant human endostatin combined with 5-Fu/DDP sequential intraperitoneal injection on the treatment of gastric cancer with malignant ascites

目的探讨重组人血管内皮抑素(恩度)联合化疗药物5-氟尿嘧啶(5-Fu)/顺铂(DDP)序贯腹腔注药治疗胃癌恶性腹水的疗效和不良反应。方法将58例胃癌恶性腹水患者随机分为治疗组(恩度+5-Fu+DDP)、对照组(5-Fu+DDP)两组,判断两组治疗胃癌恶性腹水的疗效、起效时间、生活质量及毒副反应。结果两组治疗胃癌恶性腹水的有效率:治疗组75.0%、对照组51.7%;起效时间:治疗组11.5 d、对照组17.0 d;对生活质量的影响:治疗组生活质量改善明显高于对照组;不良反应:治疗组不良反应与对照组相近。结论恩度联合5-Fu/DDP序贯腹腔注药治疗胃癌恶性腹水具有疗效高、起效时间快,可缩短疗程,提高生活质量,是治疗胃癌恶性腹水的有效方法。

[Objective ] To investigate the therapeutic effect and safety of recombinant human endostatin （Endostar） combined with chemotherapy drug 5-fluorouracil（5-Fu）/cisplatin（DDP） sequential intraperitoneal injection on the treatment of gastric cancer with malignant ascites. [ Methods ] 58 cases of gastric cancer with malignant ascites were randomly divided into treatment group （Endostar with＋5-Fu＋DDP） and control group （5-Fu＋DDP）, which are judged therapeutic effect ,onset time, quality of life and drug side effects. [ Results ] The efficiency of two groups of treating gastric cancer with malignant ascites were： treatment group 75% and control group 51.7%; the onset time were： treatment group 11.5 d and control group 17.0 d; the impact on improving the quality of life was that the treat- ment group was significantly higher than the control group; adverse reactions ：the treatment group was similar to the control group. [ Conclusions] Endostar combined with 5-Fu/DDP sequential intraperitoneal injection on the treatment of gastrie cancer with malignant aseites has high curative effect, fast onset time, and can shorten the course of treatment, improve the quality of life, which is the effective method for the treatment of gastric cancer with malignant ascites.